Set for further growth: Syntegon announces acquisition of Telstar

Gefriertrockner sowie Be- und Entladesysteme von Telstar gehören zu den wichtigsten Erweiterungen des Syntegon Portfolios für die Vialabfüllung. / Freeze-dryers as well as loading and unloading systems from Telstar are the most important portfolio enhancements for Syntegon and ideally complement its leading vial filling and isolator solutions.

Die Gefriertrocknung, auch Lyophilisierung genannt, ist ein gängiger Prozessschritt, um die langfristige Stabilität von Medikamenten wie Antibiotika, Impfstoffen oder Biologika zu gewährleisten. / Freeze-drying, also known as lyophilization, is a common process step to ensure the long-term stability of drugs, such as antibiotics, vaccines, or biologics.

Telstar Hauptquartier / Telstar Headquarters

– Important addition to the pharmaceutical processing and packaging portfolio
– Seamless solutions for lyophilized vial filling from a single source
– Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth

Syntegon is expanding its pharmaceutical processing and packaging business with the acquisition of Azbil Telstar, to date part of the Japanese Azbil Corporation, which is listed on the Tokyo Stock Exchange Prime Market. Telstar, headquartered in Terrassa (Barcelona), Spain, is a manufacturer and supplier of equipment for the global life and health science industries. With a workforce of approx. 900 employees, production plants in Spain, China, and the UK, as well as engineering, sales, and service offices all over the world, Telstar is a significant addition to Syntegon’s portfolio for liquid pharmaceutical processing. Further growth opportunities will also arise for Telstar as part of the Syntegon Group. Syntegon and Azbil have signed an agreement to not disclose any financial details. The transaction is subject to regulatory approval.

Seamless solutions from a single source

Telstar has a strong experienced team serving pharma, life sciences, and medtech customers around the world, especially in Southern and Western Europe, the U.S., and India. Freeze-dryers as well as loading and unloading systems including comprehensive services are the most important portfolio enhancements for Syntegon and ideally complement its leading vial filling and isolator solutions. Freeze-drying, also known as lyophilization, is a common process step to ensure the long-term stability of drugs, such as antibiotics, vaccines, or biologics. Telstar's business will benefit from its integration into the Syntegon Group with its complete solutions for pharmaceutical processing and packaging technology.

With the expanded portfolio, Syntegon will be in an even better position to offer both pharmaceutical manufacturers and CMOs seamless line solutions from a single source. Moreover, the Syntegon service network will be expanded significantly by the Telstar service engineers, adding geographical coverage, proximity, and application expertise.

Strategic expansion with innovative technologies

“Syntegon is world market leader in liquid vial filling. With the acquisition of Telstar, we will enhance our portfolio of innovative technologies and many successful references in the market. Our customers will benefit from even more comprehensive solutions, seamless processes, and lifecycle services,” says Torsten Türling, CEO of the Syntegon Group. “At the same time, we can jointly capture growth opportunities and expand our market presence.”

“Azbil has been strengthening its product capabilities, particularly in loading systems, and enhancing the overall competitiveness of Telstar since the acquisition in 2013. Now Azbil has decided to transfer Telstar to the company we consider best to further drive Telstar’s business. We are convinced that Syntegon will make the best use of the accumulated technological capabilities and products and will achieve sustainable growth,” says Kiyohiro Yamamoto, President and Group CEO of Azbil.

“For Telstar, the incorporation into the Syntegon Group represents a great opportunity to ensure stable business development and future growth. We look forward to bringing our knowledge, expertise, and high-value technologies for aseptic manufacturing to the joint portfolio and to becoming part of the Syntegon team, backed by a shared business culture,” says Jordi Puig, CEO of Telstar.